Leerink Partnrs Decreases Earnings Estimates for Bio-Techne

Bio-Techne Co. (NASDAQ:TECH) – Research analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for shares of Bio-Techne in a report issued on Wednesday, February 5th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will post earnings of $0.51 per share for the quarter, down from their previous estimate of $0.52. The consensus estimate for Bio-Techne’s current full-year earnings is $1.68 per share.

TECH has been the subject of several other reports. Royal Bank of Canada boosted their target price on Bio-Techne from $79.00 to $80.00 and gave the stock a “sector perform” rating in a report on Thursday, February 6th. StockNews.com upgraded Bio-Techne from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. KeyCorp boosted their target price on Bio-Techne from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Scotiabank upped their price target on Bio-Techne from $88.00 to $90.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 6th. Finally, Robert W. Baird upped their price target on Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $86.57.

Bio-Techne Stock Down 4.0 %

TECH opened at $69.92 on Monday. The business has a 50 day moving average price of $74.44 and a 200 day moving average price of $74.24. Bio-Techne has a twelve month low of $61.16 and a twelve month high of $85.57. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.26 and a current ratio of 3.94. The firm has a market cap of $11.11 billion, a P/E ratio of 70.63, a price-to-earnings-growth ratio of 5.54 and a beta of 1.27.

Bio-Techne (NASDAQ:TECH) last announced its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%.

Bio-Techne Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Investors of record on Monday, February 17th will be paid a $0.08 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.46%. Bio-Techne’s payout ratio is 32.32%.

Insider Activity at Bio-Techne

In other Bio-Techne news, CEO Kim Kelderman sold 13,392 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $77.29, for a total value of $1,035,067.68. Following the sale, the chief executive officer now directly owns 39,004 shares in the company, valued at $3,014,619.16. This represents a 25.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Bio-Techne

A number of large investors have recently bought and sold shares of the stock. Cibc World Markets Corp grew its position in Bio-Techne by 17.0% in the fourth quarter. Cibc World Markets Corp now owns 25,032 shares of the biotechnology company’s stock valued at $1,803,000 after acquiring an additional 3,631 shares during the period. Royce & Associates LP grew its position in Bio-Techne by 1.8% in the fourth quarter. Royce & Associates LP now owns 860,751 shares of the biotechnology company’s stock valued at $62,000,000 after acquiring an additional 15,353 shares during the period. Envestnet Portfolio Solutions Inc. grew its position in Bio-Techne by 317.7% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 136,243 shares of the biotechnology company’s stock valued at $9,814,000 after acquiring an additional 103,627 shares during the period. Natixis Advisors LLC grew its holdings in shares of Bio-Techne by 7.4% during the fourth quarter. Natixis Advisors LLC now owns 169,681 shares of the biotechnology company’s stock worth $12,222,000 after purchasing an additional 11,625 shares during the last quarter. Finally, Van Strum & Towne Inc. grew its holdings in shares of Bio-Techne by 20.0% during the fourth quarter. Van Strum & Towne Inc. now owns 4,800 shares of the biotechnology company’s stock worth $346,000 after purchasing an additional 800 shares during the last quarter. 98.95% of the stock is currently owned by institutional investors.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.